Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction
- 15 December 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (24), 2695-2701
- https://doi.org/10.1161/01.cir.98.24.2695
Abstract
Apart from its established effects on vessel patency after percutaneous coronary revascularization, glycoprotein IIb/IIIa receptor blockade by abciximab may improve myocardial perfusion by inhibition of the interaction of platelets and platelet aggregates with the microvasculature. We investigated the effect of abciximab with stent placement in acute myocardial infarction. In a prospective randomized trial, patients undergoing stenting in acute myocardial infarction within 48 hours after onset of symptoms were randomly assigned to receive either standard-dose heparin or abciximab plus low-dose heparin. Immediately after the procedure and at 14-day angiographic follow-up, we assessed flow velocity in the recanalized vessel with the Doppler wire and regional wall motion by the centerline method. End points were changes in papaverine-induced peak flow velocities and in wall motion indices. We assigned 98 patients to standard heparin and 102 to abciximab. We obtained 152 paired flow measurements and 151 paired left ventricular function studies. Residual stenoses of the treated lesions did not differ between the 2 groups. Improvement of peak flow velocity (mean [95% CI]: 18.1 cm/s [13.6 to 22.6 cm/s], n=80, versus 10.4 cm/s [5.4 to 15.4 cm/s], n=72, P=0.024) and wall motion index (0.44 SD/chord [0.29 to 0.59 SD/chord], n=79 versus 0. 15 SD/chord [0.00 to 0.30 SD/chord], n=72, P=0.007) was significantly greater in patients assigned to abciximab than in those on heparin alone. At follow-up, the abciximab group had a higher global left ventricular ejection fraction than the heparin group (62% [59% to 65%] versus 56% [53% to 59%], P=0.003). Abciximab had important effects beyond the maintenance of large-vessel patency. It improved the recovery of microvascular perfusion and concomitantly enhanced the recovery of contractile function in the area at risk.Keywords
This publication has 13 references indexed in Scilit:
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Recovery of Myocardial Perfusion in Acute Myocardial Infarction After Successful Balloon Angioplasty and Stent Placement in the Infarct-Related Coronary ArteryJournal of the American College of Cardiology, 1997
- GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 FabThrombosis and Haemostasis, 1997
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- The vitronectin receptor (αvβ3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cellsBiochemical Journal, 1994
- Evidence of Impaired Endothelium-Dependent Coronary Vasodilatation in Patients with Angina Pectoris and Normal Coronary AngiogramsNew England Journal of Medicine, 1993
- A Comparison of Immediate Coronary Angioplasty with Intravenous Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Value and limitations of intracoronary adenosine for the assessment of coronary flow reserveCatheterization and Cardiovascular Diagnosis, 1988
- Papavine: The ideal coronary vasodilator for investigating coronary flow reserve? A study of timing, magnitude, reproducibility, and safety of the coronary hyperemic response after intracoronary papaverineCatheterization and Cardiovascular Diagnosis, 1986